Emerson (EMR) Q4 2025 Financial Results Summary
Release Date: November 5, 2025
Emerson (NYSE: EMR) has reported its fourth-quarter and fiscal year results for the period ending September 30, 2025. The company declared a 5% cash dividend increase to $0.555 per share payable December 10, 2025, to shareholders of record on November 14, 2025. Furthermore, Emerson’s Board of Directors authorized a share repurchase of up to 50 million shares, in addition to the outstanding authorization of 60 million shares (approximately 20 million shares remain from the previous authorization).
Key Financial Highlights for Q4 2025 & FY 2025
- Underlying Orders:
- Q4 2024: 6%
-
Q4 2025: 4% (a decrease of 2% from the previous year)
-
Net Sales:
- Q4 2024: $4,619 million
- Q4 2025: $4,855 million (up 5% year-over-year)
- FY 2024: $17,492 million
-
FY 2025: $18,016 million (up 3% year-over-year)
-
Underlying Sales Growth:
- Q4 2024: 4%
-
Q4 2025: 3% (a decrease of 1% from the previous year)
-
Pretax Earnings:
- Q4 2024: $679 million
-
Q4 2025: $796 million (an increase of 17%)
-
Pretax Margin:
- Q4 2024: 14.7%
-
Q4 2025: 16.4% (an increase of 170 basis points)
-
Adjusted Segment EBITA:
- Q4 2024: $1,210 million
-
Q4 2025: $1,333 million (up 10% year-over-year)
-
EBITA Margin:
- Q4 2024: 26.2%
-
Q4 2025: 27.5% (an increase of 130 basis points)
-
GAAP Earnings Per Share:
- Q4 2024: $0.97
-
Q4 2025: $1.12 (an increase of 15%)
-
Adjusted Earnings Per Share:
- Q4 2024: $1.48
-
Q4 2025: $1.62 (an increase of 9%)
-
Operating Cash Flow:
- Q4 2024: $1,073 million
-
Q4 2025: $1,011 million (a decrease of 6%)
-
Free Cash Flow:
- Q4 2024: $905 million
- Q4 2025: $843 million (a decrease of 7%)
Full Year 2025 Highlights
- Net Sales:
-
$18,016 million (up 3% from FY 2024)
-
Pretax Earnings:
-
$2,934 million (up 45% from FY 2024)
-
GAAP Earnings Per Share:
-
$4.03 (up 43% from FY 2024)
-
Adjusted Earnings Per Share:
-
$6.00 (up 9% from FY 2024)
-
Margins:
- FY 2024 Pretax Margin: 11.5%
- FY 2025 Pretax Margin: 16.3% (an increase of 480 basis points)
Geographic Sales Growth
- Americas Sales Growth:
- Q4 2025: 6%
- Europe Sales Growth:
- Q4 2025: 3%
- Asia, Middle East & Africa Sales Growth:
- Q4 2025: 2%
2026 Outlook
Emerson is optimistic about its growth estimates for the upcoming fiscal year. The preliminary guidance for fiscal year 2026 includes:
– Net Sales Growth: ~5.5%
– Underlying Sales Growth: ~4%
– Earnings Per Share Guidance: ~$4.73 – $4.93
– Expected Free Cash Flow: ~$3.5B – $3.6B
Summary
Emerson’s Q4 2025 results showcase a strong upward trend in earnings and margins, alongside a cautious approach to sales growth. With the announcement of an increased dividend and a significant share repurchase program, the company remains committed to returning value to shareholders while positioning itself for future growth amid evolving market conditions.
Here are the extracted tables from the provided press release:
CONSOLIDATED STATEMENTS OF INCOME (Amounts in millions)
| Quarter Ended September 30, | Year Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2025 | 2024 | 2025 | |
| Cost of sales | $4,619 | $4,855 | $17,492 | $18,016 |
| SG&A expenses | $2,248 | $2,335 | $8,607 | $8,497 |
| Gain on subordinated interest | $1,315 | $1,330 | $5,142 | $5,103 |
| Loss on Copeland note receivable | $— | $— | ($79) | $— |
| Other deductions, net | $— | $— | $279 | $— |
| Interest expense, net | $359 | $302 | $1,434 | $1,245 |
| Interest income from related party1 | $18 | $92 | $175 | $237 |
| Earnings from continuing operations before income taxes | $— | $— | ($86) | $— |
| Income taxes | $679 | $796 | $2,020 | $2,934 |
| Earnings from continuing operations | $149 | $160 | $415 | $696 |
| Discontinued operations, net of tax | $530 | $636 | $1,605 | $2,238 |
| Net earnings | $438 | $1 | $350 | $8 |
| Less: Noncontrolling interests in subsidiaries | $968 | $637 | $1,955 | $2,246 |
| Net earnings common stockholders | ($28) | $— | ($13) | ($47) |
| Earnings common stockholders | $996 | $637 | $1,968 | $2,293 |
| Earnings from continuing operations | $558 | $636 | $1,618 | $2,285 |
| Discontinued operations | $438 | $1 | $350 | $8 |
| Net earnings common stockholders | $996 | $637 | $1,968 | $2,293 |
| Diluted avg. shares outstanding | 573.9 | 565.5 | 574.0 | 566.7 |
| Diluted earnings per share common stockholders | ||||
| Earnings from continuing operations | $0.97 | $1.12 | $2.82 | $4.03 |
| Discontinued operations | $0.76 | $— | $0.61 | $0.01 |
| Diluted earnings per common share | $1.73 | $1.12 | $3.43 | $4.04 |
CONSOLIDATED BALANCE SHEETS (Amounts in millions)
| Assets | Year Ended Sept 30, | |
|---|---|---|
| Cash and equivalents | $3,588 | $1,544 |
| Receivables, net | $2,927 | $3,101 |
| Inventories | $2,180 | $2,213 |
| Other current assets | $1,497 | $1,725 |
| Total current assets | $10,192 | $8,583 |
| Property, plant & equipment, net | $2,807 | $2,871 |
| Goodwill | $18,067 | $18,193 |
| Other intangible assets | $10,436 | $9,458 |
| Other | $2,744 | $2,859 |
| Total assets | $44,246 | $41,964 |
| Liabilities and equity | ||
| Short-term borrowings and current maturities of long-term debt | $532 | $4,797 |
| Accounts payable | $1,335 | $1,384 |
| Accrued expenses | $3,875 | $3,616 |
| Total current liabilities | $5,742 | $9,797 |
| Long-term debt | $7,155 | $8,319 |
| Other liabilities | $3,840 | $3,550 |
| Equity | ||
| Common stockholders’ equity | $21,636 | $20,282 |
| Noncontrolling interests in subsidiaries | $5,873 | $16 |
| Total equity | $27,509 | $20,298 |
| Total liabilities and equity | $44,246 | $41,964 |
